ramucirumab + capecitabine + cisplatin

This regimen is a **combination therapy** of ramucirumab (a fully human monoclonal antibody that targets VEGFR2), capecitabine (an oral prodrug of 5-fluorouracil, a pyrimidine antimetabolite), and cisplatin (a platinum-based chemotherapeutic). Ramucirumab acts by binding to and inhibiting VEGFR2, blocking VEGF-mediated angiogenesis required for tumor growth. Capecitabine is metabolized into 5-fluorouracil, which inhibits DNA synthesis by targeting thymidylate synthase. Cisplatin forms DNA crosslinks that inhibit DNA replication and transcription, leading to apoptosis. The **combination is studied primarily as first-line therapy for advanced or metastatic gastric and gastroesophageal junction cancer**[1][3][5].

Other names

RAM + CAPE + CDDPramucirumab + capecitabine + cisplatin